Aura Biosciences, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$112.8M | -$96.1M | -$85.0M | -$60.3M | -$35.2M |
| Cash from operations | -$84.7M | -$79.8M | -$63.8M | -$54.6M | -$32.4M |
| Capital expenditure | $447,000 | $1.3M | $709,000 | $1.1M | $2.1M |
| Free cash flow | -$85.2M | -$81.1M | -$64.6M | -$55.7M | -$34.5M |
| Impairments | $0 | $0 | $0 | $0 | — |
| Total assets | $169.4M | $182.5M | $255.1M | $223.9M | $160.0M |
| Total liabilities | $32.5M | $30.5M | $29.2M | $28.4M | $7.7M |
Shares outstanding 103.4M · Free float 93.5%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.